AATS: American Association for Thoracic Surgery.
Watch the AATS Leadership Video
 
Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung

Back to 85th Annual Meeting
Back to Program Outline


F17. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung
Young T Kim, Hee J Kang, Jeen Lee, Sun J Park, Seung H Lee, Curi Ann; SeoulGyenggi-do, Republic of Korea

Objective: DNA hypermethylation in promoter regions has been studied for various types of cancer. However, there is no clear evidence that shows methylation status can predict long-term survival in lung cancer.
Methods: We collected tissue from 72 cases of lung adenocarcinoma. The cancer and normal lung tissue were tested for DNA hypermethylation using methylation-specific PCR (MSP). The genes tested were p16INK4a, RARβP2, DAPK and MGMT, and GSTP. The status of the analyzed DNA methylation focused on long-term outcome as well as clinical variables, including cancer stage.
Results: DNA hyper-methylations were observed in 83%(60/72) for p16INK4a, 63%(45/72) for RARβP2, 32%(23/72) for DAPK, 17%(12/72) for MGMT, and 46%(33/72) for GSTP from the cancer tissue. From normal lung tissue, methylation was positive in 75%(54/72) for p16INK4a, 24%(17/72) for RARβP2, 10%(7/72) for DAPK, 6%(4/72) for MGMT, and 33%(24/72) for GSTP. During the mean follow-up period of 18±11(1-40) months, 25 patients(35%) developed recurrence and 13 died. Hypomethylation of DAPK in cancer tissue(p=0.04) and hypermethylation of RARβP2 in normal tissue(p=0.01) were significant variables that affected long-term survival. In multivariate analysis, male gender(p=0.04), hypomethylation of DAPK from cancer tissue(p=0.03), and hypermethylation of RARβP2 from normal tissue(p=0.01) were risk factors for poor survival. Pathologic stage(p=0.01) and hypomethylation of DAPK(p=0.07) from normal tissue were risk factors for recurrence.
Conclusions: DNA methylation status of CpG island seems to be a useful predictor of long-term outcome for adenocarcinoma of the lung. Further studies, including multiple genes, are necessary to increase its usefulness in the clinical setting.


Back to 85th Annual Meeting
Back to Program Outline

We Model Excellence
Follow AATS on Facebook
Copyright © American Association for Thoracic Surgery. All rights reserved.
Read the Privacy Policy.
IMPORTANT REMINDER: The preceding information is intended only to provide
general guidance and not as a definitive basis for diagnosis or treatment in any particular case.
It is very important that you consult a doctor about any specific medical problem or question.